Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Background: Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront su...

Full description

Bibliographic Details
Main Authors: Sumit Sahni, Christopher Nahm, Christoph Krisp, Mark P. Molloy, Shreya Mehta, Sarah Maloney, Malinda Itchins, Nick Pavlakis, Stephen Clarke, David Chan, Anthony J. Gill, Viive M. Howell, Jaswinder Samra, Anubhav Mittal
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Oncology
Subjects:
pancreatic ductal adenocarcinoma
biomarkers
neoadjuvant chemotherapy
proteomics
SWATH-MS
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00237/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00237/full

Similar Items